Pfizer announces phase 3 TALAPRO-3 study of talzenna plus Xtandi significantly improves rPFS in metastatic prostate cancer: New York Friday, March 20, 2026, 09:00 Hrs [IST] Pfizer ...

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

Pfizer Inc. PFE shares are up during Thursday’s trading session after the company shared data from Talzenna plus Xtandi’s investigational treatment regimen for HRR gene-mutated metastatic ...

Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial for prostate cancer. Read more here.

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...

An Anglesey man wants to know why it took so long for Betsi health chiefs to start treatment on his "aggressive cancer" - a ...

BCUHB patient waited three times longer than he should have for prostate cancer treatment. Delays likely advanced his condition, ombudsman finds.

No significant improvement seen in overall survival with addition of hormone therapy to post-radical prostatectomy radiotherapy.

This is a rare opportunity for me personally, this is my only hope to extend my life by any real period at all." ...

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...

A groundbreaking randomized clinical trial led by Chair of Radiation Oncology Daniel Spratt at University Hospitals Seidman Cancer Center in Cleveland has identified the first validated predictive ...